A review of antithrombotic therapy for transcatheter aortic valve replacement

Estella M. Davis, Stacey K. Friedman, Thomas M. Baker

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aortic stenosis (AS) is a common valvular pathological finding in older adults. A latent period followed by rapid progression after the onset of symptoms can result in a high rate of death if left untreated. Aortic valve replacement (AVR) remains the standard of care for patients with severe symptomatic AS; however, due to comorbidities and age, patients may be ineligible for surgical AVR. Transcatheter AVR (TAVR) is an alternative treatment for patients with severe symptomatic AS for whom surgery is not an option. The most recent guidelines and consensus statement discussing TAVR support the use of antithrombotic therapy during and after TAVR procedures to prevent thrombotic complications. Intravenous unfractionated heparin titrated to target activated clotting times during the procedure and dual antiplatelet therapy before and after TAVR with aspirin and clopidogrel may be used. However, it is unclear which antithrombotic regimen may provide optimal protection for early and late thrombotic events in patients who undergo TAVR. This review evaluates the current guidelines, trials, and registry data discussing antithrombotic regimens for TAVR.

Original languageEnglish
Pages (from-to)59-72
Number of pages14
JournalPostgraduate Medicine
Volume125
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Aortic Valve Stenosis
clopidogrel
Aortic Valve
Guidelines
Therapeutics
Standard of Care
Surgical Instruments
Aspirin
Registries
Heparin
Comorbidity
Mortality
Transcatheter Aortic Valve Replacement

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

A review of antithrombotic therapy for transcatheter aortic valve replacement. / Davis, Estella M.; Friedman, Stacey K.; Baker, Thomas M.

In: Postgraduate Medicine, Vol. 125, No. 1, 01.2013, p. 59-72.

Research output: Contribution to journalArticle

Davis, Estella M. ; Friedman, Stacey K. ; Baker, Thomas M. / A review of antithrombotic therapy for transcatheter aortic valve replacement. In: Postgraduate Medicine. 2013 ; Vol. 125, No. 1. pp. 59-72.
@article{cba848d1a7af46a4adb27e4bdadba566,
title = "A review of antithrombotic therapy for transcatheter aortic valve replacement",
abstract = "Aortic stenosis (AS) is a common valvular pathological finding in older adults. A latent period followed by rapid progression after the onset of symptoms can result in a high rate of death if left untreated. Aortic valve replacement (AVR) remains the standard of care for patients with severe symptomatic AS; however, due to comorbidities and age, patients may be ineligible for surgical AVR. Transcatheter AVR (TAVR) is an alternative treatment for patients with severe symptomatic AS for whom surgery is not an option. The most recent guidelines and consensus statement discussing TAVR support the use of antithrombotic therapy during and after TAVR procedures to prevent thrombotic complications. Intravenous unfractionated heparin titrated to target activated clotting times during the procedure and dual antiplatelet therapy before and after TAVR with aspirin and clopidogrel may be used. However, it is unclear which antithrombotic regimen may provide optimal protection for early and late thrombotic events in patients who undergo TAVR. This review evaluates the current guidelines, trials, and registry data discussing antithrombotic regimens for TAVR.",
author = "Davis, {Estella M.} and Friedman, {Stacey K.} and Baker, {Thomas M.}",
year = "2013",
month = "1",
doi = "10.3810/pgm.2013.01.2625",
language = "English",
volume = "125",
pages = "59--72",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "1",

}

TY - JOUR

T1 - A review of antithrombotic therapy for transcatheter aortic valve replacement

AU - Davis, Estella M.

AU - Friedman, Stacey K.

AU - Baker, Thomas M.

PY - 2013/1

Y1 - 2013/1

N2 - Aortic stenosis (AS) is a common valvular pathological finding in older adults. A latent period followed by rapid progression after the onset of symptoms can result in a high rate of death if left untreated. Aortic valve replacement (AVR) remains the standard of care for patients with severe symptomatic AS; however, due to comorbidities and age, patients may be ineligible for surgical AVR. Transcatheter AVR (TAVR) is an alternative treatment for patients with severe symptomatic AS for whom surgery is not an option. The most recent guidelines and consensus statement discussing TAVR support the use of antithrombotic therapy during and after TAVR procedures to prevent thrombotic complications. Intravenous unfractionated heparin titrated to target activated clotting times during the procedure and dual antiplatelet therapy before and after TAVR with aspirin and clopidogrel may be used. However, it is unclear which antithrombotic regimen may provide optimal protection for early and late thrombotic events in patients who undergo TAVR. This review evaluates the current guidelines, trials, and registry data discussing antithrombotic regimens for TAVR.

AB - Aortic stenosis (AS) is a common valvular pathological finding in older adults. A latent period followed by rapid progression after the onset of symptoms can result in a high rate of death if left untreated. Aortic valve replacement (AVR) remains the standard of care for patients with severe symptomatic AS; however, due to comorbidities and age, patients may be ineligible for surgical AVR. Transcatheter AVR (TAVR) is an alternative treatment for patients with severe symptomatic AS for whom surgery is not an option. The most recent guidelines and consensus statement discussing TAVR support the use of antithrombotic therapy during and after TAVR procedures to prevent thrombotic complications. Intravenous unfractionated heparin titrated to target activated clotting times during the procedure and dual antiplatelet therapy before and after TAVR with aspirin and clopidogrel may be used. However, it is unclear which antithrombotic regimen may provide optimal protection for early and late thrombotic events in patients who undergo TAVR. This review evaluates the current guidelines, trials, and registry data discussing antithrombotic regimens for TAVR.

UR - http://www.scopus.com/inward/record.url?scp=84875907716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875907716&partnerID=8YFLogxK

U2 - 10.3810/pgm.2013.01.2625

DO - 10.3810/pgm.2013.01.2625

M3 - Article

VL - 125

SP - 59

EP - 72

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 1

ER -